Targeting IL-17 in tandem with antibiotic therapy may aid in treating late-stage pneumonic plague or pneumonia caused by other agents in which IL-17-driven neutrophil infiltration in the airways contributes to pathogenesis. Here, IL17A is linked to pneumonia.